anastrozole has been researched along with Menopause in 16 studies
Menopause: The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a prospective randomized trial, we evaluated the efficacy of using either a combination of anastrozole and goserelin for 6 months or goserelin alone for 6 months after conservative surgery for severe endometriosis." | 9.11 | The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. ( Gezgin, T; Gul, N; Ozer, S; Soysal, ME; Soysal, S, 2004) |
| "This is a 5-year interim analysis of a 10-year, prospective, observational, IRB approved study investigating the incidence of breast cancer in women presenting with symptoms of hormone deficiency treated with subcutaneous testosterone (T) implants or, T combined with the aromatase inhibitor anastrozole (A), i." | 7.79 | Reduced breast cancer incidence in women treated with subcutaneous testosterone, or testosterone with anastrozole: a prospective, observational study. ( Dimitrakakis, C; Glaser, RL, 2013) |
| "Endocrine treatments of breast cancer patients antagonize estrogen and may lead to consequences of estrogen deprivation including menopausal symptoms." | 6.71 | Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. ( Ameye, L; Carbonez, A; Christiaens, MR; Morales, L; Neven, P; Paridaens, R; Timmerman, D; Van Huffel, S; Van Limbergen, E; Vergote, I, 2004) |
| "Tamoxifen has been the principal adjuvant hormonal therapy in pre- and postmenopausal women with hormone receptor-positive breast cancer for nearly 20 years." | 6.42 | Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole. ( Carlson, RW; Henderson, IC, 2003) |
| "In a prospective randomized trial, we evaluated the efficacy of using either a combination of anastrozole and goserelin for 6 months or goserelin alone for 6 months after conservative surgery for severe endometriosis." | 5.11 | The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. ( Gezgin, T; Gul, N; Ozer, S; Soysal, ME; Soysal, S, 2004) |
| "Androstenedione, the main circulating ovarian hormone present after menopause, has been shown to positively correlate with poor spatial memory in an ovary-intact rodent model of follicular depletion, and to impair spatial memory when administered exogenously to surgically menopausal ovariectomized rats." | 3.81 | Pharmacological blockade of the aromatase enzyme, but not the androgen receptor, reverses androstenedione-induced cognitive impairments in young surgically menopausal rats. ( Acosta, JI; Alderete, TJ; Bimonte-Nelson, HA; Camp, BW; Demers, LM; Koebele, SV; Mennenga, SE; Mousa, AA; Tsang, CW, 2015) |
| "This is a 5-year interim analysis of a 10-year, prospective, observational, IRB approved study investigating the incidence of breast cancer in women presenting with symptoms of hormone deficiency treated with subcutaneous testosterone (T) implants or, T combined with the aromatase inhibitor anastrozole (A), i." | 3.79 | Reduced breast cancer incidence in women treated with subcutaneous testosterone, or testosterone with anastrozole: a prospective, observational study. ( Dimitrakakis, C; Glaser, RL, 2013) |
| "Postmenopausal women with large primary oestrogen receptor-rich (>20 fmol/mg protein or 80 histoscore) breast cancers have been treated neoadjuvantly with either letrozole (2." | 3.71 | Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy. ( Anderson, TJ; Cameron, DA; Dixon, JM; Miller, WR, 2001) |
| "Endocrine treatments of breast cancer patients antagonize estrogen and may lead to consequences of estrogen deprivation including menopausal symptoms." | 2.71 | Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. ( Ameye, L; Carbonez, A; Christiaens, MR; Morales, L; Neven, P; Paridaens, R; Timmerman, D; Van Huffel, S; Van Limbergen, E; Vergote, I, 2004) |
| "Tamoxifen has been the principal adjuvant hormonal therapy in pre- and postmenopausal women with hormone receptor-positive breast cancer for nearly 20 years." | 2.42 | Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole. ( Carlson, RW; Henderson, IC, 2003) |
| "Advanced breast cancer patients' quality of life was high, showing the efficacy of endocrine therapy, but women with primary disease reported better physical, social, and functional well-being and fewer breast cancer concerns." | 1.30 | Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. ( Benson, S; Cella, D; Fallowfield, LJ; Howell, A; Leaity, SK, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 9 (56.25) | 29.6817 |
| 2010's | 5 (31.25) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Salmon, RJ | 1 |
| Glaser, RL | 1 |
| Dimitrakakis, C | 1 |
| Mennenga, SE | 1 |
| Koebele, SV | 1 |
| Mousa, AA | 1 |
| Alderete, TJ | 1 |
| Tsang, CW | 1 |
| Acosta, JI | 1 |
| Camp, BW | 1 |
| Demers, LM | 1 |
| Bimonte-Nelson, HA | 1 |
| Goodwin, PJ | 1 |
| Pritchard, KI | 1 |
| Kanematsu, M | 1 |
| Morimoto, M | 1 |
| Honda, J | 1 |
| Nagao, T | 1 |
| Nakagawa, M | 1 |
| Takahashi, M | 1 |
| Tangoku, A | 1 |
| Sasa, M | 1 |
| Koloszar, S | 1 |
| Pal, Z | 1 |
| Kereszturi, A | 1 |
| Vajda, G | 1 |
| Pal, A | 1 |
| Daru, J | 1 |
| Carlson, RW | 1 |
| Henderson, IC | 1 |
| Soysal, S | 1 |
| Soysal, ME | 1 |
| Ozer, S | 1 |
| Gul, N | 1 |
| Gezgin, T | 1 |
| Kammerer, S | 1 |
| Morales, L | 1 |
| Neven, P | 1 |
| Timmerman, D | 1 |
| Christiaens, MR | 1 |
| Vergote, I | 1 |
| Van Limbergen, E | 1 |
| Carbonez, A | 1 |
| Van Huffel, S | 1 |
| Ameye, L | 1 |
| Paridaens, R | 1 |
| de Cremoux, P | 1 |
| Diéras, V | 1 |
| Poupon, MF | 1 |
| Magdelénat, H | 1 |
| Sigal-Zafrani, B | 1 |
| Fourquet, A | 1 |
| Pierga, JY | 1 |
| Spano, JP | 1 |
| Khayat, D | 1 |
| Delozier, T | 1 |
| Goss, PE | 1 |
| Hadji, P | 1 |
| Subar, M | 1 |
| Abreu, P | 1 |
| Thomsen, T | 1 |
| Banke-Bochita, J | 1 |
| Fallowfield, LJ | 1 |
| Leaity, SK | 1 |
| Howell, A | 1 |
| Benson, S | 1 |
| Cella, D | 1 |
| Miller, WR | 1 |
| Dixon, JM | 1 |
| Cameron, DA | 1 |
| Anderson, TJ | 1 |
| Baum, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Personalised Electronic Record Supported Two-Stage Observational Study of Sleep in Patients With Breast Cancer[NCT05093426] | 226 participants (Actual) | Observational | 2022-01-15 | Completed | |||
| Safety, Feasibility and Efficacy of Vitamin D Supplementation in Women With Metastatic Breast Cancer (SAFE-D)[NCT02186015] | Phase 2 | 43 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy. A Prospective Placebo Double Blind Study[NCT01016665] | 71 participants (Actual) | Interventional | 2005-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Assessment of fatigue using the Piper Fatigue Scale at weeks 0 and 8. The Piper Fatigue Scale is the average of 22 numeric items, with higher scores indicating greater fatigue [range of scores: 0-10]. Change is calculated as the fatigue score at 8 weeks minus fatigue score at 0 weeks. Change was not assessed for participants in the 'no cholecalciferol' arm since they did not receive weekly supplementation and were not followed over time. (NCT02186015)
Timeframe: 0, 8 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Cholecalciferol | -0.5 |
"Assessment of quality of life using the functional assessment of cancer therapy-breast symptoms at weeks 0 and 8. Scores range from 0-40 with higher scores indicating better quality of life.~Change was calculated as week 8 score minus week 0 score. Change was not assessed for participants in the 'no cholecalciferol' arm since they did not receive weekly supplementation and were not followed over time." (NCT02186015)
Timeframe: 0, 8 weeks
| Intervention | score on a scale (Median) |
|---|---|
| Cholecalciferol | 0 |
Assessment of quality of life using the functional assessment of cancer therapy- endocrine symptoms at weeks 0 and 8. Scores range from 0-76 with higher scores indicating better quality of life. Change was not assessed for participants in the 'no cholecalciferol' arm since they did not receive weekly supplementation and were not followed over time. (NCT02186015)
Timeframe: 0, 8 weeks
| Intervention | score on a scale (Median) |
|---|---|
| Cholecalciferol | 9 |
Assessment of mood using the Patient Health Questionnaire 8 (PHQ-8) at weeks 0 and 8. The PHQ-8 ranges from 0-24 with higher scores indicating more distress. Change was assessed as PHQ-8 score at 8 weeks minus 0 weeks. Change was not assessed for participants in the 'no cholecalciferol' arm since they did not receive weekly supplementation and were not followed over time. (NCT02186015)
Timeframe: 0, 8 weeks
| Intervention | score on a scale (Median) |
|---|---|
| Cholecalciferol | -1 |
Assessment of muscle function using a hand dynamometer at weeks 0 and 8. Change in dominant handgrip strength in kilograms was calculated as 8 weeks minus 0 weeks. Change was not assessed for participants in the 'no cholecalciferol' arm since they did not receive weekly supplementation and were not followed over time. (NCT02186015)
Timeframe: 0, 8 weeks
| Intervention | kilograms (Median) |
|---|---|
| Cholecalciferol | -0.2 |
Change in laboratory serum value of 25(OH)D at 8 weeks post-supplementation for participants who received weekly supplementation of 50,000 IUs of vitamin D3. Change is expressed as laboratory serum value of 25(OH)D at 8 weeks minus baseline. Change was not assessed for participants in the 'no cholecalciferol' arm since they did not receive weekly supplementation and were not followed over time. (NCT02186015)
Timeframe: 0, 8 weeks
| Intervention | ng/ml (Median) |
|---|---|
| Cholecalciferol | 32 |
Assessment of sleep using the Pittsburgh Sleep Quality Index (PSQI) at weeks 0 and 8. Scores range from 0-21 with higher scores indicating poorer sleep quality. Change was calculated as week 8 minus week 0 PSQI. Change was not assessed for participants in the 'no cholecalciferol' arm since they did not receive weekly supplementation and were not followed over time. (NCT02186015)
Timeframe: 0, 8 weeks
| Intervention | score on a scale (Median) |
|---|---|
| Cholecalciferol | -1 |
Assessment of pain using the Beck Pain Scale at weeks 0 and 8. This is a Likert scale item where a score of 0 corresponds to no pain and a score of 10 corresponds to worst pain. Change is calculated as the worst pain rating at 8 weeks minus the worst pain rating at 0 weeks.Change was not assessed for participants in the 'no cholecalciferol' arm since they did not receive weekly supplementation and were not followed over time. (NCT02186015)
Timeframe: 0, 8 weeks
| Intervention | score on a scale (Median) |
|---|---|
| Cholecalciferol | 0 |
4 reviews available for anastrozole and Menopause
| Article | Year |
|---|---|
Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Adminis | 2003 |
[Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2004 |
[Aromatase inhibitors in adjuvant setting in breast cancer].
Topics: Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Ne | 2004 |
A vision for the future?
Topics: Anastrozole; Breast Neoplasms; Estradiol; Female; Fulvestrant; Goserelin; Humans; Menopause; Nitrile | 2001 |
3 trials available for anastrozole and Menopause
| Article | Year |
|---|---|
The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial.
Topics: Adult; Anastrozole; Aromatase Inhibitors; Bone Density; Drug Administration Schedule; Drug Therapy, | 2004 |
Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients.
Topics: Anastrozole; Aromatase Inhibitors; Belgium; Body Mass Index; Breast Neoplasms; Data Interpretation, | 2004 |
Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers | 2007 |
9 other studies available for anastrozole and Menopause
| Article | Year |
|---|---|
[De-escalation in aromatase inhibitors prescription for menopausal women with positive hormonal receptors breast cancer].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2023 |
Reduced breast cancer incidence in women treated with subcutaneous testosterone, or testosterone with anastrozole: a prospective, observational study.
Topics: Adult; Aged; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Estrogen Replacement Therapy; Fema | 2013 |
Pharmacological blockade of the aromatase enzyme, but not the androgen receptor, reverses androstenedione-induced cognitive impairments in young surgically menopausal rats.
Topics: Anastrozole; Androgen Antagonists; Androstenedione; Animals; Aromatase Inhibitors; Brain; Cognition | 2015 |
Obesity and hormone therapy in breast cancer: an unfinished puzzle.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estrogen Antag | 2010 |
The time since last menstrual period is important as a clinical predictor for non-steroidal aromatase inhibitor-related arthralgia.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Female; | 2011 |
Effects of aromatase inhibitor on menopausal hyperplasia in a case of obesity.
Topics: Administration, Oral; Aged; Anastrozole; Aromatase Inhibitors; Atrophy; Endometrial Hyperplasia; End | 2012 |
[New prevention strategies against breast cancer and cervical carcinoma. What can you advice to your patients].
Topics: Adolescent; Adult; Age Factors; Anastrozole; Anticarcinogenic Agents; Breast Neoplasms; Celecoxib; C | 2003 |
Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chem | 1999 |
Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chem | 1999 |
Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chem | 1999 |
Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chem | 1999 |
Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Estr | 2001 |